학술논문
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Document Type
article
Author
Source
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Subject
Language
English
ISSN
2041-1723
Abstract
Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.